This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
reputable news agency
proofread
Paternal metformin use not linked to major congenital malformations
![Paternal metformin use not linked to major congenital malformations](https://scx1.b-cdn.net/csz/news/800a/2024/paternal-metformin-use.jpg)
Paternal use of metformin in monotherapy is not associated with an increased risk for major congenital malformations (MCMs), according to a study published online June 18 in the Annals of Internal Medicine.
Ran S. Rotem, Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the association between paternal metformin use during spermatogenesis and MCMs in newborns to assess the potential adverse intergenerational effect of metformin in a nationally representative cohort study. Data were included for 383,851 live births that occurred in 1999 to 2020.
The researchers found that the prevalence of cardiometabolic morbidity was substantially higher among fathers who used metformin during spermatogenesis and their spouses compared with unexposed fathers.
The crude odds ratio for paternal metformin exposure in all formulations and MCMs was 1.28 (95 percent confidence interval, 1.01 to 1.64), but the odds ratio after adjustment was 1.00 (95 percent confidence interval, 0.76 to 1.31). The adjusted odds ratio was 0.86 (95 percent confidence interval, 0.60 to 1.23) and 1.36 (95 percent confidence interval, 1.00 to 1.85) for metformin in monotherapy and for metformin in polytherapy, respectively.
"Future research should examine the intergenerational effects of paternal cardiometabolic morbidity and related drug treatments while applying specific focus to polytherapies and aiming to disentangle potential drug-related effects from effects exerted by the underlying clinical indication," the authors write.
More information: Ran S. Rotem et al, Paternal Use of Metformin During the Sperm Development Period Preceding Conception and Risk for Major Congenital Malformations in Newborns, Annals of Internal Medicine (2024). DOI: 10.7326/M23-1405
Sarah Martins da Silva, Paternal and Maternal Metformin Use and the Risk for Major Congenital Malformations, Annals of Internal Medicine (2024). DOI: 10.7326/M24-0883
Copyright © 2024 HealthDay. All rights reserved.